Effect of supplementation in regression of cervical intraepithelial neoplasia 1

The effect of selenium supplementation on regression and metabolic profiles in women with cervical intraepithelial neoplasia 1(CIN1)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201412215623N32

Enrollment

Registered

2015-01-06

Start date

2014-03-18

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical intraepithelial neoplasia 1(CIN1). Malignant neoplasm of cervix uteri

Interventions

Intervention 1: Control group: Placebo tablet, daily, for 6 months orally. Intervention 2: Intervention group: Selenium tablet, 200 µg, daily, for 6 months orally.

Eligibility

Sex/Gender

Female

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Women aged 18-55 years; diagnosed with cervical intraepithelial neoplasia 1

Exclusion criteria

Exclusion criteria: Women who had a history of cervical cancer or other cancers of the lower genital tract History of hysterectomy or destructive therapy of the cervix Pregnant women

Design outcomes

Primary

Measure	Time frame
Cervical intraepithelial neoplasia grade 1. Timepoint: Baseline and End-of-trial. Method of measurement: Colposcopy.	—

Secondary

Measure	Time frame
Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Calculation using HOMA formula.;Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;HDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;High-sensitivity C-reactive Protein. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Fasting blood sugar. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.	—

Measure

Time frame

Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Calculation using HOMA formula.;Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;HDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;High-sensitivity C-reactive Protein. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Fasting blood sugar. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_r@yahoo.com+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026